CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...